⌕
ImmunityBio · IBRX · Nasdaq
Tenet 51 · Mixed
Compare
$6.70+7.03%At closeTenet 51 · Mixed
$6.70+0.44 (+7.03%)
At close: Nov 18, 2026, 4:00 PM ET· Nasdaq · USD

ImmunityBio (IBRX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is IBRX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 16, 2026 · 08:42 ET
ImmunityBio, Inc. (IBRX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript

ImmunityBio, Inc. ( IBRX ) UBS Global Biopharma Conference 2026 November 16, 2026 5:40 AM EST Company Participants Richard Adcock - President, CEO & Director Conference Call Participants Dejia Zhang Presentation Dejia Zh…

IBRX +7.0% todayRead at source ↗
● Business WireNov 11, 2026 · 08:30 ET
New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced findings from a national survey of military service members and veterans with non-muscle i…

IBRX +7.0% todayRead at source ↗
● Business WireNov 10, 2026 · 21:31 ETCOMPANY'S OWN WORDS
ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced members of the senior leadership team will speak at the upcoming Jefferies Global Healthca…

IBRX +7.0% todayRead at source ↗
● Zacks Investment ResearchNov 10, 2026 · 11:06 ET
IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%

ImmunityBio's revenues jump 53% on Anktiva adoption, but a wider-than-expected loss, sequential sales decline and rising expenses weigh on shares.…

IBRX +7.0% todayRead at source ↗
● The Motley FoolNov 9, 2026 · 15:18 ET
Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?

ImmunityBio's quarterly product sales rose 53% from a year earlier, but they slipped from the prior quarter and missed Wall Street's estimate. Even after Monday's drop, the stock trades at roughly 39 times its annualized…

IBRX +7.0% todayRead at source ↗
● BenzingaNov 9, 2026 · 10:31 ET
ImmunityBio Reports Wider Quarterly Loss

ImmunityBio Inc. (NASDAQ:IBRX) stock is trading lower on Monday after the company's third-quarter earnings missed expectations.…

IBRX +7.0% todayRead at source ↗
● Zacks Investment ResearchNov 9, 2026 · 09:51 ET
ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates

ImmunityBio (IBRX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.07 per share a year ago.…

IBRX +7.0% todayRead at source ↗
● Business WireNov 9, 2026 · 07:30 ETCOMPANY'S OWN WORDS
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial results for the third qua…

IBRX +7.0% todayRead at source ↗
● Business WireNov 9, 2026 · 07:00 ETCOMPANY'S OWN WORDS
ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

JERUSALEM & CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) (“ImmunityBio”) and Rafa Laboratories Ltd. (TASE: RAFA) (“Rafa”) today announced that the Israeli Ministry of Health (MoH) has granted ap…

IBRX +7.0% todayRead at source ↗
● Business WireNov 9, 2026 · 06:30 ETCOMPANY'S OWN WORDS
ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.00…

IBRX +7.0% todayRead at source ↗
● Business WireNov 4, 2026 · 08:00 ETCOMPANY'S OWN WORDS
ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

CULVER CITY, Calif. & DUBLIN--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the first patients in Europe received treatment with ANKTIVA® (nogapendekin …

IBRX +7.0% todayRead at source ↗
● Defense WorldOct 27, 2026 · 04:20 ET
ImmunityBio, Inc. $IBRX Stake Trimmed by Davidson Kahn Capital Management LLC

Davidson Kahn Capital Management LLC lessened its stake in ImmunityBio, Inc. (NASDAQ: IBRX) by 50.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm own…

IBRX +7.0% todayRead at source ↗
● Business WireOct 21, 2026 · 07:30 ETCOMPANY'S OWN WORDS
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced completion of the database lock for Cohort A of QUILT-2.005 (NCT02138734), its randomized, controlled, reg…

IBRX +7.0% todayRead at source ↗
● BenzingaOct 19, 2026 · 11:52 ET
ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment

A recent study published in the Journal of Urology revealed promising long-term results for ImmunityBio, Inc. (NASDAQ:IBRX) and its immunotherapy treatment, ANKTIVA.…

IBRX +7.0% todayRead at source ↗
● Business WireOct 16, 2026 · 11:49 ETCOMPANY'S OWN WORDS
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Jour…

IBRX +7.0% todayRead at source ↗
● Zacks Investment ResearchOct 15, 2026 · 14:00 ET
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer

IBRX wins expanded FDA approval for Anktiva plus BCG, covering all patients with BCG-unresponsive NMIBC and broadening its commercial opportunity.…

IBRX +7.0% todayRead at source ↗
● BenzingaOct 15, 2026 · 07:01 ET
ImmunityBio Stock Climbs Thursday: What's Going On?

ImmunityBio Inc. (NASDAQ:IBRX) shares are trading higher Thursday after the FDA expanded the approved indication for its bladder cancer immunotherapy ANKTIVA to include BCG-unresponsive non-muscle-invasive bladder cancer…

IBRX +7.0% todayRead at source ↗
● Business WireOct 14, 2026 · 16:18 ET
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for …

IBRX +7.0% todayRead at source ↗
● Defense WorldOct 11, 2026 · 02:44 ET
ImmunityBio (NASDAQ:IBRX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Survey

Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and ImmunityBio (NASDAQ: IBRX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the s…

IBRX +7.0% todayRead at source ↗
● Business WireOct 8, 2026 · 08:30 ETCOMPANY'S OWN WORDS
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Global Chief Scientific …

IBRX +7.0% todayRead at source ↗
● Defense WorldOct 8, 2026 · 05:01 ET
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a s…

IBRX +7.0% todayRead at source ↗
● BenzingaOct 2, 2026 · 13:20 ET
ImmunityBio Stock Jumps: What's Going On?

ImmunityBio Inc. (NASDAQ:IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.…

IBRX +7.0% todayRead at source ↗
● Defense WorldSep 24, 2026 · 03:45 ET
State Street Corp Grows Holdings in ImmunityBio, Inc. $IBRX

State Street Corp raised its position in ImmunityBio, Inc. (NASDAQ: IBRX) by 20.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund own…

IBRX +7.0% todayRead at source ↗
● Zacks Investment ResearchSep 18, 2026 · 04:46 ET
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?

ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.…

IBRX +7.0% todayRead at source ↗
NVDA16−2.9%
ANT13
MSFT5+0.4%
P4−1.0%

Article counts from the last market-wide feed page, across every symbol we track and not just IBRX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.